Ascendis Pharma A/S (ASND) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $225.25, -0.60% vs the prior close of $226.62.
- Volume 680.31K shares, 0.9x its 50-day average.
- New SEC filings: 6-K (Oct 16, 2026).
- No new insider buys or sales reported since the prior session.
ASND dips 0.6% to $225.25. Closed at $225.25, -0.60% vs the prior close of $226.62. Day range $223.78–$226.63, opened at $226.62.
ASND daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — ASND dips 0.6% to $225.25
- Closed at $225.25, -0.60% vs the prior close of $226.62. Day range $223.78–$226.63, opened at $226.62.
- Volume was 680.31K shares, 0.9x its 50-day average of 725.87K.
- Price is -7.7% vs its 50-day average ($244.15) and -4.8% vs its 200-day average ($236.51).
- 52-week range $186.05–$282.15; today's close sits at 41% of that range, 20.2% below the 52-week high.
Oct 15, 2026 — ASND ends flat (-0.2%) to $226.62
- Closed at $226.62, -0.17% vs the prior close of $227.00. Day range $226.06–$234.01, opened at $230.40.
- Volume was 404.00K shares, 0.6x its 50-day average of 727.51K — lighter than usual.
- Price is -7.4% vs its 50-day average ($244.64) and -4.1% vs its 200-day average ($236.43).
- 52-week range $186.05–$282.15; today's close sits at 42% of that range, 19.7% below the 52-week high.
Oct 14, 2026 — ASND rises 1.7% to $227.00
- Closed at $227.00, +1.70% vs the prior close of $223.21. Day range $222.00–$227.83, opened at $222.54.
- Volume was 995.70K shares, 1.4x its 50-day average of 723.43K.
- Price is -7.3% vs its 50-day average ($244.99) and -4.0% vs its 200-day average ($236.35).
- 52-week range $186.05–$282.15; today's close sits at 43% of that range, 19.5% below the 52-week high.
- SEC filings that day: 6-K.
Oct 13, 2026 — ASND dips 1.7% to $223.21
- Closed at $223.21, -1.67% vs the prior close of $227.00. Day range $222.21–$228.91, opened at $225.99.
- Volume was 592.20K shares, 0.8x its 50-day average of 724.05K.
- Price is -9.0% vs its 50-day average ($245.35) and -5.5% vs its 200-day average ($236.26).
- 52-week range $186.05–$282.15; today's close sits at 39% of that range, 20.9% below the 52-week high.
Oct 12, 2026 — ASND dips 1.0% to $227.00
- Closed at $227.00, -0.97% vs the prior close of $229.23. Day range $226.66–$229.23, opened at $229.00.
- Volume was 667.40K shares, 0.9x its 50-day average of 720.88K.
- Price is -7.6% vs its 50-day average ($245.75) and -3.9% vs its 200-day average ($236.21).
- 52-week range $186.05–$282.15; today's close sits at 43% of that range, 19.5% below the 52-week high.
Oct 9, 2026 — ASND rises 2.9% to $229.23
- Closed at $229.23, +2.94% vs the prior close of $222.69. Day range $223.96–$233.96, opened at $225.08.
- Volume was 815.70K shares, 1.1x its 50-day average of 714.07K.
- Price is -6.9% vs its 50-day average ($246.09) and -2.9% vs its 200-day average ($236.12).
- 52-week range $186.05–$282.15; today's close sits at 45% of that range, 18.8% below the 52-week high.
Oct 8, 2026 — ASND dips 2.5% to $222.69, a 3-month low
- Closed at $222.69, -2.50% vs the prior close of $228.41. Day range $219.52–$227.98, opened at $227.83.
- Volume was 924.10K shares, 1.3x its 50-day average of 705.73K.
- Price is -9.7% vs its 50-day average ($246.53) and -5.6% vs its 200-day average ($236.02).
- 52-week range $186.05–$282.15; today's close sits at 38% of that range, 21.1% below the 52-week high.
Oct 7, 2026 — ASND rises 1.0% to $228.41
- Closed at $228.41, +1.04% vs the prior close of $226.05. Day range $223.05–$229.00, opened at $224.36.
- Volume was 820.50K shares, 1.2x its 50-day average of 700.89K.
- Price is -7.6% vs its 50-day average ($247.11) and -3.2% vs its 200-day average ($235.90).
- 52-week range $186.05–$282.15; today's close sits at 44% of that range, 19.0% below the 52-week high.
Oct 6, 2026 — ASND dips 0.9% to $226.05
- Closed at $226.05, -0.87% vs the prior close of $228.03. Day range $222.71–$230.91, opened at $229.21.
- Volume was 1.09M shares, 1.6x its 50-day average of 686.36K.
- Price is -8.7% vs its 50-day average ($247.63) and -4.1% vs its 200-day average ($235.76).
- 52-week range $186.05–$282.15; today's close sits at 42% of that range, 19.9% below the 52-week high.
Oct 5, 2026 — ASND ends flat (+0.1%) to $228.03
- Closed at $228.03, +0.07% vs the prior close of $227.87. Day range $226.84–$230.73, opened at $229.66.
- Volume was 783.20K shares, 1.2x its 50-day average of 678.50K.
- Price is -8.1% vs its 50-day average ($248.18) and -3.2% vs its 200-day average ($235.65).
- 52-week range $186.05–$282.15; today's close sits at 44% of that range, 19.2% below the 52-week high.
Oct 2, 2026 — ASND ends flat (+0.2%) to $227.87
- Closed at $227.87, +0.25% vs the prior close of $227.31. Day range $225.20–$229.02, opened at $227.63.
- Volume was 641.40K shares, 1.0x its 50-day average of 671.84K.
- Price is -8.4% vs its 50-day average ($248.70) and -3.3% vs its 200-day average ($235.57).
- 52-week range $186.05–$282.15; today's close sits at 44% of that range, 19.2% below the 52-week high.
ASND latest news & SEC filings
Every SEC filing by or about ASND in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 16, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Oct 14, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 29, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 28, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 15, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 15, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 9, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 9, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Bodenhoff Mads sold 3,000 shares at $270.19 (≈$810.57K) on Sep 8, 2026
- Bodenhoff Mads sold 3,000 shares at $270.19 (≈$810.57K) on Sep 8, 2026
- Bodenhoff Mads sold 3,000 shares at $270.19 (≈$810.57K) on Sep 8, 2026
- Bodenhoff Mads sold 3,000 shares at $270.19 (≈$810.57K) on Sep 8, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 9, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 8, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 3, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Holtug Lars sold 236 shares at $264.13 (≈$62.33K) on Sep 2, 2026
- Holtug Lars sold 236 shares at $264.13 (≈$62.33K) on Sep 2, 2026
- Holtug Lars sold 236 shares at $264.13 (≈$62.33K) on Sep 2, 2026
- Holtug Lars sold 236 shares at $264.13 (≈$62.33K) on Sep 2, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 2, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 31, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Aug 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Bienaime Jean Jacques bought 1,100 shares at $245.85 (≈$270.44K) on Aug 14, 2026
- Bienaime Jean Jacques bought 900 shares at $246.91 (≈$222.22K) on Aug 14, 2026
- Bienaime Jean Jacques bought 1,100 shares at $245.85 (≈$270.44K) on Aug 14, 2026
- Bienaime Jean Jacques bought 900 shares at $246.91 (≈$222.22K) on Aug 14, 2026
- Bienaime Jean Jacques bought 1,100 shares at $245.85 (≈$270.44K) on Aug 14, 2026
- Bienaime Jean Jacques bought 900 shares at $246.91 (≈$222.22K) on Aug 14, 2026
- …plus 2 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 13, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade ASND
- How much it moves: over the last 20 sessions the average daily move was 1.40% (largest 6.1%).
- Liquidity: about 790.65K shares (≈$178.09M) trade per day on average.
- 52-week position: $225.25 vs a range of $186.05–$282.15 (41% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 17 open-market buys, 8 sales; latest: Mads Bodenhoff sold 3,000 shares on Sep 8, 2026.
- Latest filings: 6-K Oct 16, 2026; 6-K Oct 14, 2026; 6-K Sep 29, 2026.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
ASND market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 226.62 | 226.63 | 223.78 | 225.25 | 680.31K |
| Oct 15, 2026 | 230.40 | 234.01 | 226.06 | 226.62 | 404.00K |
| Oct 14, 2026 | 222.54 | 227.83 | 222.00 | 227.00 | 995.70K |
| Oct 13, 2026 | 225.99 | 228.91 | 222.21 | 223.21 | 592.20K |
| Oct 12, 2026 | 229.00 | 229.23 | 226.66 | 227.00 | 667.40K |
| Oct 9, 2026 | 225.08 | 233.96 | 223.96 | 229.23 | 815.70K |
| Oct 8, 2026 | 227.83 | 227.98 | 219.52 | 222.69 | 924.10K |
| Oct 7, 2026 | 224.36 | 229.00 | 223.05 | 228.41 | 820.50K |
| Oct 6, 2026 | 229.21 | 230.91 | 222.71 | 226.05 | 1.09M |
| Oct 5, 2026 | 229.66 | 230.73 | 226.84 | 228.03 | 783.20K |
| Oct 2, 2026 | 227.63 | 229.02 | 225.20 | 227.87 | 641.40K |
| Oct 1, 2026 | 228.03 | 229.88 | 226.00 | 227.31 | 805.90K |
| Sep 30, 2026 | 227.97 | 230.97 | 226.18 | 227.83 | 926.20K |
| Sep 29, 2026 | 227.42 | 229.89 | 223.70 | 228.07 | 741.90K |
| Sep 28, 2026 | 226.00 | 231.14 | 224.80 | 230.05 | 747.50K |
| Sep 25, 2026 | 230.13 | 230.43 | 224.26 | 225.60 | 420.00K |
| Sep 24, 2026 | 223.00 | 231.13 | 220.23 | 230.70 | 1.17M |
| Sep 23, 2026 | 236.83 | 237.98 | 220.60 | 223.13 | 1.22M |
| Sep 22, 2026 | 239.09 | 240.69 | 234.67 | 237.57 | 548.30K |
| Sep 21, 2026 | 238.66 | 241.51 | 237.00 | 237.59 | 823.00K |
About Ascendis Pharma A/S
Ascendis Pharma A/S (ASND) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in HELLERUP. State of incorporation: Denmark. Fiscal year ends December 31. SEC CIK 1612042.
ASND board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Jean Jacques Bienaime | Director | Sep 28, 2026 |
| Albert Cha | Director | Mar 18, 2026 |
| William Fairey | Director | Mar 18, 2026 |
| Lars Holtug | Director | Sep 3, 2026 |
| Siham Imani | Director | Mar 18, 2026 |
| Jan Moller Mikkelsen | Director | Mar 18, 2026 |
| Lisa Morrison | Director | Mar 18, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Mads Bodenhoff | SVP & PAO | Sep 9, 2026 |
| Flemming Steen Jensen | See Remarks | May 12, 2026 |
| Michael Wolff Jensen | EVP, Chief Legal Officer | Mar 18, 2026 |
| Anni Lotte Kirstine Sonderbjerg Pedersen | EVP & Chief Admin Officer | Mar 18, 2026 |
| Scott Thomas Smith | EVP & Chief Financial Officer | Jun 2, 2026 |
| Kennett Sprogoe | See Remarks | Mar 18, 2026 |
| Aimee Shu | EVP & Chief Medical Officer | Mar 18, 2026 |
| Jay Donovan Wu | EVP & President US Market | Mar 18, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 8, 2026 | Mads Bodenhoff | Sale | 3,000 | $270.19 |
| Sep 8, 2026 | Mads Bodenhoff | Sale | 3,000 | $270.19 |
| Sep 8, 2026 | Mads Bodenhoff | Sale | 3,000 | $270.19 |
| Sep 8, 2026 | Mads Bodenhoff | Sale | 3,000 | $270.19 |
| Sep 2, 2026 | Lars Holtug | Sale | 236 | $264.13 |
| Sep 2, 2026 | Lars Holtug | Sale | 236 | $264.13 |
| Sep 2, 2026 | Lars Holtug | Sale | 236 | $264.13 |
| Sep 2, 2026 | Lars Holtug | Sale | 236 | $264.13 |
| Aug 14, 2026 | Jean Jacques Bienaime | Buy | 1,100 | $245.85 |
| Aug 14, 2026 | Jean Jacques Bienaime | Buy | 900 | $246.91 |
| Aug 14, 2026 | Jean Jacques Bienaime | Buy | 1,100 | $245.85 |
| Aug 14, 2026 | Jean Jacques Bienaime | Buy | 900 | $246.91 |
| Aug 14, 2026 | Jean Jacques Bienaime | Buy | 1,100 | $245.85 |
| Aug 14, 2026 | Jean Jacques Bienaime | Buy | 900 | $246.91 |
| Aug 14, 2026 | Jean Jacques Bienaime | Buy | 1,100 | $245.85 |
ASND financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| No annual XBRL figures available (foreign filers often report on Form 20-F). | ||||
Latest balance sheet: total assets $—, total liabilities $—, cash $—.
ASND earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| No 8-K earnings releases in recent filings. | ||
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on ASND
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.